The gastrointestinal tract and ventilator-associated pneumonia.
The gastrointestinal tract is believed to play an important role in ventilator-associated pneumonia (VAP), because during critical illness the stomach often is colonized with enteric Gram-negative bacteria. These are the same bacteria that frequently are isolated from the sputum of patients with VAP. Interventions such as selective decontamination of the digestive tract (SDD), use of sucralfate for stress ulcer prophylaxis, and enteral feeding strategies that preserve gastric pH, or lessen the likelihood of pulmonary aspiration, are used to decrease the incidence of VAP. A review of both meta-analyses and large randomized controlled trials providing Level I evidence on these topics has led to the following conclusions. First, SDD substantially decreases the incidence of VAP and may have a modest positive effect on mortality. However, there is strong contravening evidence that SDD promotes infections by Gram-positive bacteria. In the context of an emerging public health crisis from the steady rise in drug-resistant Gram-positive bacteria, we cannot endorse the general use of SDD to prevent VAP. Rather, therapy should be focused on strategies other than antibiotic prophylaxis. Second, in patients who are at risk for clinically important gastrointestinal bleeding, a histamine-2 receptor antagonist should be used for stress ulcer prophylaxis, rather than sucralfate, because histamine-2 receptor antagonist provides substantially better protection without substantially increasing the risk of VAP. Third, post-pyloric enteral feeding may reduce the incidence of VAP.
Cardiovascular Research Institute, University of California, San Francsico, USA. richkallet@earthlink.net
Richard H
RH
Kallet
Thomas E
TE
Quinn
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics; D003666:Decontamination; D019317:Evidence-Based Medicine; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006090:Gram-Negative Bacteria / Q000472:pathogenicity; D017721:Hospital Costs; D006801:Humans; D007902:Length of Stay; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012122:Ventilators, Mechanical / Q000009:adverse effects*
D000900:Anti-Bacterial Agents